NIP
VRNA

Nicholas Investment Partners’s Verona Pharma VRNA Stock Holding History

Nicholas Investment Partners’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-198,845
Closed -$18.8M – 238
2025
Q2 		$18.8M Buy
198,845
+14,128
+8% +$1.05M 1.67% 9
2025
Q1 		$11.7M Buy
184,717
+29,903
+19% +$1.79M 1.21% 18
2024
Q4 		$7.19M Buy
+154,814
New +$5.81M 0.63% 52
2024
Q1 		– Sell
-169,126
Closed -$3.36M – 225
2023
Q4 		$3.36M Sell
169,126
-993,863
-85% -$14.7M 0.39% 100
2023
Q3 		$19M Sell
1,162,989
-366
-0% -$7.05K 1.42% 19
2023
Q2 		$24.6M Buy
1,163,355
+222,055
+24% +$4.74M 1.68% 17
2023
Q1 		$18.9M Buy
+941,300
New +$20.3M 1.44% 24

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nicholas Investment Partners's VRNA Position: Q3 2025 in Review

Nicholas Investment Partners sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 198,845 shares — an estimated $18.8M sold.

Nicholas Investment Partners first reported a position in VRNA in Q1 2023 and held it in 7 quarters. The position peaked at $24.6M in Q2 2023. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Nicholas Investment Partners reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Nicholas Investment Partners sold 198,845 Verona Pharma shares in Q3 2025, an estimated $18.8M.
  • Nicholas Investment Partners first reported a position in Verona Pharma in Q1 2023 and held it in 7 quarters.
  • Nicholas Investment Partners's Verona Pharma position peaked at $24.6M in Q2 2023.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Nicholas Investment Partners's 13F filing for Q3 2025, filed 14 Nov 2025.